

## Sulfamethoxazole



Click image to enlarge

$C_{10}H_{11}N_3O_3S$

253.28

Benzenesulfonamide, 4-amino-*N*-(5-methyl-3-isoxazolyl)-;

*N*<sup>1</sup>-(5-Methyl-3-isoxazolyl)sulfanilamide [723-46-6]; UNII: JE42381TNV.

### DEFINITION

Sulfamethoxazole contains NLT 98.0% and NMT 102.0% of sulfamethoxazole ( $C_{10}H_{11}N_3O_3S$ ), calculated on the dried basis.

### IDENTIFICATION

#### Change to read:

- **A. SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Infrared Spectroscopy*: 197K ▲ or 197A ▲ (IRA 1-May-2021)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

### ASSAY

#### Change to read:

#### PROCEDURE

**Buffer:** 13.6 g/L of [potassium dihydrogen phosphate](#) adjusted with a 20-g/L solution of [potassium hydroxide](#) to a pH of 5.3

**Mobile phase:** [Methanol](#) and *Buffer* (30:70)

**Standard solution:** 0.1 mg/mL ▲▲ (IRA 1-May-2021) of [USP Sulfamethoxazole RS](#) ▲▲ (IRA 1-May-2021) in *Mobile phase*. Sonicate at 45° with intermittent shaking to dissolve before final dilution.

▲**System suitability solution:** 0.1 mg/mL each of [USP Sulfamethoxazole RS](#) and [USP Sulfamethoxazole Related Compound A RS](#) in *Mobile phase*. Sonicate at 45° with intermittent shaking to dissolve before final dilution. ▲ (IRA 1-May-2021)

**Sample solution:** 0.1 mg/mL of Sulfamethoxazole in *Mobile phase*. Sonicate at 45° with intermittent shaking to dissolve before final dilution.

#### Chromatographic system

(See [Chromatography](#) (621), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 210 nm

**Column:** 4-mm × 25-cm; 5-μm packing [L7](#)

**Flow rate:** 0.9 mL/min

**Injection volume:** 20 μL

## System suitability

**Samples:** ▲ *System suitability solution* and ▲ (IRA 1-May-2021) *Standard solution*

[NOTE—The relative retention times for sulfamethoxazole and sulfamethoxazole related compound A are 1.0 and 1.2, respectively.]

### Suitability requirements

**Resolution:** NLT 3.5 between sulfamethoxazole and sulfamethoxazole related compound A,

▲ *System suitability solution* ▲ (IRA 1-May-2021)

**Relative standard deviation:** NMT 0.73%, ▲ *Standard solution* ▲ (IRA 1-May-2021)

## Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of sulfamethoxazole ( $C_{10}H_{11}N_3O_3S$ ) in the portion of Sulfamethoxazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of sulfamethoxazole from the *Sample solution*

$r_S$  = peak response of sulfamethoxazole from the *Standard solution*

$C_S$  = concentration of [USP Sulfamethoxazole RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Sulfamethoxazole in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

## IMPURITIES

- **RESIDUE ON IGNITION** (281): NMT 0.1%

### Change to read:

- **ORGANIC IMPURITIES**

**Buffer, Mobile phase, ▲ *System suitability solution*, ▲ (IRA 1-May-2021) and Chromatographic system:** Proceed as directed in the Assay.

▲ (IRA 1-May-2021)

**Peak identification solution:** 1 µg/mL each of [USP Sulfamethoxazole Related Compound A RS](#), [USP Sulfamethoxazole Related Compound B RS](#), [USP Sulfamethoxazole Related Compound C RS](#), [USP Sulfanilic Acid RS](#), and [USP Sulfanilamide RS](#) in *Mobile phase*. Sonicate, if necessary, to dissolve before final dilution.

▲ **Sensitivity solution:** 0.3 µg/mL of [USP Sulfamethoxazole RS](#) in *Mobile phase*. Sonicate, if necessary, to dissolve before final dilution. ▲ (IRA 1-May-2021)

**Standard solution:** 1 µg/mL each of [USP Sulfamethoxazole RS](#) and [USP Sulfamethoxazole Related Compound F RS](#) in *Mobile phase*. Sonicate, if necessary, to dissolve before final dilution.

**Sample solution:** 1 mg/mL of Sulfamethoxazole in *Mobile phase*. Sonicate at 45° with intermittent shaking to dissolve before final dilution.

## System suitability

**Samples:** *System suitability solution*, ▲ *Sensitivity solution*, ▲ (IRA 1-May-2021) and *Standard solution*

### Suitability requirements

**Resolution:** NLT 3.5 between sulfamethoxazole and sulfamethoxazole related compound A, ▲ ▲ (IRA 1-May-2021) *System suitability solution*

**Relative standard deviation:** NMT 5.0% <sup>▲</sup>each <sup>▲</sup>(IRA 1-May-2021) for sulfamethoxazole <sup>▲</sup>and sulfamethoxazole related compound F, <sup>▲</sup>(IRA 1-May-2021) *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution* <sup>▲</sup>(IRA 1-May-2021)

## Analysis

**Samples:** *Peak identification solution, Standard solution, and Sample solution*

Calculate the percentage of sulfamethoxazole related compound F in the portion of Sulfamethoxazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of sulfamethoxazole related compound F from the *Sample solution*

$r_S$  = peak response of sulfamethoxazole related compound F from the *Standard solution*

$C_S$  = concentration of [USP Sulfamethoxazole Related Compound F RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Sulfamethoxazole in the *Sample solution* (mg/mL)

Calculate the percentage of any <sup>▲</sup>other <sup>▲</sup>(IRA 1-May-2021) individual impurity in the portion of Sulfamethoxazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of any <sup>▲</sup>other <sup>▲</sup>(IRA 1-May-2021) individual impurity from the *Sample solution*

$r_S$  = peak response of sulfamethoxazole from the *Standard solution*

$C_S$  = concentration of [USP Sulfamethoxazole RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Sulfamethoxazole in the *Sample solution* (mg/mL)

**Acceptance criteria:** See [Table 1](#). The reporting threshold is 0.03%.

**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Sulfanilic acid	0.26	0.10
Sulfanilamide	0.35	0.10
Sulfamethoxazole related compound F	0.45	0.10
Sulfamethoxazole related compound C	0.50	0.10
Sulfamethoxazole	1.0	—
Sulfamethoxazole related compound A	1.2	0.10
Sulfamethoxazole related compound B	2.1	0.10

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Any individual unspecified impurity	—	0.10
Total impurities	—	0.30

## SPECIFIC TESTS

- **LOSS ON DRYING** (731)

**Analysis:** Dry at 105° for 4 h.

**Acceptance criteria:** NMT 0.5%

## ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed, light-resistant containers. Store at room temperature.

### Change to read:

- **USP REFERENCE STANDARDS** (11)

[USP Sulfamethoxazole RS](#)

[USP Sulfamethoxazole Related Compound A RS](#)

*N*-{4-[*N*-(5-Methylisoxazol-3-yl)sulfamoyl]phenyl}acetamide.

$C_{12}H_{13}N_3O_4S$  295.31

[USP Sulfamethoxazole Related Compound B RS](#)

4-Amino-*N*-{4-[*N*-(5-methylisoxazol-3-yl)sulfamoyl]phenyl}benzenesulfonamide.

$C_{16}H_{16}N_4O_5S_2$  408.45

[USP Sulfamethoxazole Related Compound C RS](#)

5-Methylisoxazol-3-amine.

$C_4H_6N_2O$  **▲98.11▲** (IRA 1-May-2021)

[USP Sulfamethoxazole Related Compound F RS](#)

4-Amino-*N*-(3-methylisoxazol-5-yl)benzenesulfonamide.

$C_{10}H_{11}N_3O_3S$  253.28

[USP Sulfanilamide RS](#)

4-Aminobenzenesulfonamide.

$C_6H_8N_2O_2S$  172.20

[USP Sulfanilic Acid RS](#)

4-Aminobenzenesulfonic acid.

$C_6H_7NO_3S$  173.19

## Page Information:

Not Applicable

## Current DocID:

